How did Immunovant Inc. (IMVT) surprise investors with its report?

A share price of Immunovant Inc. [IMVT] is currently trading at $4.38, up up 3.30%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IMVT shares have gain 2.10% over the last week, with a monthly amount glided 7.62%, and seem to be holding up well over a long-time horizon.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 8, June 2022, Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022. In a post published today on Yahoo Finance, Immunovant plans to initiate two placebo-controlled Phase 3 clinical trials of batoclimab in thyroid eye disease (TED) in the second half of calendar year 2022 with top-line data expected for both in the first half of calendar year 2025.

From an analyst’s perspective:

Immunovant Inc. [NASDAQ: IMVT] stock has seen the most recent analyst activity on December 08, 2021, when Wells Fargo initiated its Equal Weight rating and assigned the stock a price target of $9. Previously, Robert W. Baird downgraded its rating to Neutral on August 03, 2021, and dropped its price target to $10. On August 02, 2021, downgrade downgraded it’s rating to Underperform and revised its price target to $7 on the stock. Stifel downgraded its rating to a Hold and decreased its price target to $9 on June 01, 2021. Guggenheim downgraded its rating to a Neutral. UBS started tracking with a Buy rating for this stock on October 28, 2020, and assigned it a price target of $61. In a note dated October 12, 2020, Guggenheim initiated an Buy rating and iterated a target price of $63 on this stock.

Immunovant Inc. experienced fluctuations in its stock price throughout the past year between $3.14 and $9.53. Currently, Wall Street analysts expect the stock to reach $9.50 within the next 12 months. Immunovant Inc. [NASDAQ: IMVT] shares were valued at $4.38 at the most recent close of the market. An investor can expect a potential return of 116.89% based on the average price forecast.

Analyzing the IMVT fundamentals

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.29 points at the first support level, and at 4.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.43, and for the 2nd resistance point, it is at 4.49.

Immunovant Inc. [IMVT] reported earnings per share of -$0.41 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.38/share, meaning a difference of $-0.03 and a surprise factor of -7.90%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.36 per share as compared to estimates of -$0.33 per share, a difference of $-0.03 representing a surprise of -9.10%.

Ratios To Look Out For

A current ratio of 11.50 is a noteworthy aspect of Immunovant Inc. [NASDAQ:IMVT]. In addition, the Quick Ratio stands at 11.52 and the Cash Ratio stands at 11.09.

Transactions by insiders

In the past 3 months, 0 insiders have purchased 0 shares, and 3 have sold 2,423 shares. Recent insider trading involved Butchko Julia G., Chief Dev. & Tech. Officer, that happened on Jul 27 when 510.0 shares were sold. Chief Executive Officer, Salzmann Peter completed a deal on Jul 27 to sell 1528.0 shares. Meanwhile, Chief Medical Officer Macias William L. sold 322.0 shares on Jul 22.